Fragile X testing in obstetrics and gynaecology in Canada (Q33374885)

26 July 2017

Fragile X testing in obstetrics and gynaecology in Canada (English)

1 reference

26 July 2017

0 references

0 references

0 references

7

François Audibert

1 reference

26 July 2017

Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada(SOGC)

1

1 reference

26 July 2017

Prenatal Diagnosis Committee of the Canadian College of Medical Geneticists(CCMG)

2

1 reference

26 July 2017

David Chitayat

3

1 reference

26 July 2017

Philip R Wyatt

4

1 reference

26 July 2017

R Douglas Wilson

5

1 reference

26 July 2017

Jo-Ann Johnson

6

1 reference

26 July 2017

Victoria Allen

8

1 reference

26 July 2017

Alain Gagnon

9

1 reference

26 July 2017

Sylvie Langlois

10

1 reference

26 July 2017

Claire Blight

11

1 reference

26 July 2017

Jo-Ann Brock

12

1 reference

26 July 2017

Valerie Désilets

13

1 reference

26 July 2017

Sandra A Farell

14

1 reference

26 July 2017

Michael Geraghty

15

1 reference

26 July 2017

Tanya Nelson

16

1 reference

26 July 2017

Sarah M Nikkel

17

1 reference

26 July 2017

David Skidmore

18

1 reference

26 July 2017

Andrea Shugar

19

1 reference

26 July 2017

1 September 2008

1 reference

Journal of Obstetrics and Gynaecology Canada

26 July 2017

1 reference

26 July 2017

30

1 reference

26 July 2017

9

1 reference

26 July 2017

837-846

1 reference

Cystic fibrosis carrier testing in pregnancy in Canada

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Preconceptional and prenatal screening for fragile X syndrome: experience with 40,000 tests.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Perspectives and molecular diagnosis of the fragile X syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

FMR1 and the fragile X syndrome: human genome epidemiology review

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Fragile X syndrome: an update and review for the primary pediatrician

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Prevalence and instability of fragile X alleles: implications for offering fragile X prenatal diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Molecular genetic advances in fragile X syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Repeat instability: mechanisms of dynamic mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Fragile X-associated tremor/ataxia syndrome (FXTAS).

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

FXTAS: a progressive neurologic syndrome associated with Fragile X premutation

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Fragile X-associated tremor/ataxia syndrome and movements disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Expanded clinical phenotype of women with the FMR1 premutation.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Evidence for, and a spectrum of, neurological involvement in carriers of the fragile X pre-mutation: FXTAS and beyond.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

The female and the fragile X reviewed

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Familial premature ovarian failure in female premutated carriers of fragile X syndrome: a case report and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Association of FMR1 repeat size with ovarian dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

The FMR1 premutation and reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Premature ovarian failure in the fragile X syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

1 reference

7 January 2021

Fragile X syndrome: diagnostic and carrier testing

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Screening for fragile X syndrome: information needs for health planners

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Ethical, legal, and social concerns about expanded newborn screening: fragile X syndrome as a prototype for emerging issues

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

Cost-effectiveness analysis of prenatal population-based fragile X carrier screening

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

ACOG committee opinion. No. 338: Screening for fragile X syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2932949-8

7 January 2021

10.1016/S1701-2163(16)32949-8

Identifiers

DOI

0 references

1 reference